Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Pierre-Yves Berclaz

A 52-Week, Open-Label Study Evaluating the Safety and Efficacy of Tabalumab, an Anti-B-Cell-Activating Factor Monoclonal Antibody, for Rheumatoid Arthritis

Arthritis Research and Therapy

English

Rho GTPase Rac1 Is Critical for Neutrophil Migration Into the Lung

English

Related publications

Efficacy and Safety of Subcutaneous Tabalumab, a Monoclonal Antibody to B-Cell Activating Factor, in Patients With Systemic Lupus Erythematosus: Results From ILLUMINATE-2, a 52-Week, Phase III, Multicentre, Randomised, Double-Blind, Placebo-Controlled Study

Annals of the Rheumatic Diseases

English

Long-Term Efficacy and Safety of RPC4046, an Anti-Interleukin-13 Monoclonal Antibody, in Patients With Eosinophilic Esophagitis: Results From the Open-Label Extension of the HEROES Study

Journal of Allergy and Clinical Immunology

Allergy

Immunology

2019

English

A Multicentre Open-Label Safety and Efficacy Study of Tetrodotoxin for Cancer Pain

Current Oncology

Oncology

2011

English

SAT0236 Long-Term Safety and Efficacy of Upadacitinib (ABT-494), an Oral Jak-1 Inhibitor in Patients With Rheumatoid Arthritis in an Open Label Extension Study

2018

English

Anti-CCP Antibody and Rheumatoid Factor Positivity in a Case of Tuberculosis Arthritis

Turkish Journal of Rheumatology

2010

English

Safety and Efficacy of Tofacitinib for Up to 9.5 Years in the Treatment of Rheumatoid Arthritis: Final Results of a Global, Open-Label, Long-Term Extension Study

Arthritis Research & Therapy

2019

English

Safety and Efficacy From an 8 Week Double-Blind Trial and a 26 Week Open-Label Extension of Asenapine in Adolescents With Schizophrenia

Journal of Child and Adolescent Psychopharmacology

English

Efficacy and Safety of an Intravenous Monoclonal Anti-HBs in Chronic Hepatitis B Patients

Liver International

Hepatology

2001

English

B Cell Therapy for Rheumatoid Arthritis: The Rituximab (Anti-Cd20) Experience

Annals of the Rheumatic Diseases

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Pierre-Yves Berclaz

A 52-Week, Open-Label Study Evaluating the Safety and Efficacy of Tabalumab, an Anti-B-Cell-Activating Factor Monoclonal Antibody, for Rheumatoid Arthritis

Rho GTPase Rac1 Is Critical for Neutrophil Migration Into the Lung

Related publications

Efficacy and Safety of Subcutaneous Tabalumab, a Monoclonal Antibody to B-Cell Activating Factor, in Patients With Systemic Lupus Erythematosus: Results From ILLUMINATE-2, a 52-Week, Phase III, Multicentre, Randomised, Double-Blind, Placebo-Controlled Study

Long-Term Efficacy and Safety of RPC4046, an Anti-Interleukin-13 Monoclonal Antibody, in Patients With Eosinophilic Esophagitis: Results From the Open-Label Extension of the HEROES Study

A Multicentre Open-Label Safety and Efficacy Study of Tetrodotoxin for Cancer Pain

SAT0236 Long-Term Safety and Efficacy of Upadacitinib (ABT-494), an Oral Jak-1 Inhibitor in Patients With Rheumatoid Arthritis in an Open Label Extension Study

Anti-CCP Antibody and Rheumatoid Factor Positivity in a Case of Tuberculosis Arthritis

Safety and Efficacy of Tofacitinib for Up to 9.5 Years in the Treatment of Rheumatoid Arthritis: Final Results of a Global, Open-Label, Long-Term Extension Study

Safety and Efficacy From an 8 Week Double-Blind Trial and a 26 Week Open-Label Extension of Asenapine in Adolescents With Schizophrenia

Efficacy and Safety of an Intravenous Monoclonal Anti-HBs in Chronic Hepatitis B Patients

B Cell Therapy for Rheumatoid Arthritis: The Rituximab (Anti-Cd20) Experience